Scientific Citations

Scientists discuss and refer to previous scientific publications in their scientific articles. These citations to the scientific literature are an integral part of the scientific process. Some of the hundreds of scientific citations to the published articles of Edward Tobinick MD, the founder of the INR, are listed below. Dr. Tobinick’s scientific findings have been published in multiple, peer-reviewed medical journals, including BMC Neurology, Clinical Drug Investigation, Clinical Therapeutics, CNS Drugs, Current Alzheimer Research, Current Medical Research and Opinion, Drug Discovery Today, Expert Review of Neurotherapeutics;  and in medical and scientific textbooks, including Mechanisms of Neuroinflammation (InTech, 2017); and New Therapeutics for Traumatic Brain Injury (Academic Press, 2017).

[divider]

Citations to publications of Edward Tobinick M.D.

In 2017:

  1. Allison, D.J., A.R. Josse, D.A. Gabriel, P. Klentrou, and D.S. Ditor, Targeting inflammation to influence cognitive function following spinal cord injury: a randomized clinical trial. Spinal Cord, 2017. 55(1): p. 26-32.
  2. Bagyinszky, E., V.V. Giau, K. Shim, K. Suk, S.S.A. An, and S. Kim, Role of inflammatory molecules in the Alzheimer’s disease progression and diagnosis. J Neurol Sci, 2017. 376: p. 242-254.
  3. Barami, K., Letter: Low-Pressure Hydrocephalus in Children: A Case Series and Review of the Literature. Neurosurgery, 2017. 81(5): p. E66.
  4. Chang, R., J. Knox, J. Chang, A. Derbedrossian, V. Vasilevko, D. Cribbs, R.J. Boado, W.M. Pardridge, and R.K. Sumbria, Blood-Brain Barrier Penetrating Biologic TNF-alpha Inhibitor for Alzheimer’s Disease. Mol Pharm, 2017. 14(7): p. 2340-2349.
  5. Chang, R., K.L. Yee, and R.K. Sumbria, Tumor necrosis factor alpha Inhibition for Alzheimer’s Disease. J Cent Nerv Syst Dis, 2017. 9: p. 1179573517709278.
  6. Clark, I.A., An unsound AAN Practice Advisory on poststroke etanercept. Expert Rev Neurother, 2017. 17(3): p. 215-217.
  7. Clark, I.A. and B. Vissel, The meteorology of cytokine storms, and the clinical usefulness of this knowledge. Semin Immunopathol, 2017. 39(5): p. 505-516.
  8. Dasli, S., M. Topdag, A. Mutlu, A. Kara, and M. Ozturk, Prophylactic etanercept treatment in cisplatin ototoxicity. Eur Arch Otorhinolaryngol, 2017. 274(10): p. 3577-3583.
  9. Deardorff, W.J. and G.T. Grossberg, Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics. Expert Rev Neurother, 2017. 17(1): p. 17-32.
  10. Decourt, B., D.K. Lahiri, and M.N. Sabbagh, Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease. Curr Alzheimer Res, 2017. 14(4): p. 412-425.
  11. Donat, C.K., G. Scott, S.M. Gentleman, and M. Sastre, Microglial Activation in Traumatic Brain Injury. Front Aging Neurosci, 2017. 9: p. 208.
  12. Frega, G., I. Garajova, A. Palloni, M.A. Barbera, M. Trossello Pastore, L. Faccioli, L. Spinardi, S. De Lorenzo, M. Cubelli, M.A. Pantaleo, G. Biasco, and G. Brandi, Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients. Oncology, 2017.
  13. Hollander, M.C., L.L. Latour, D. Yang, H. Ishii, Z. Xiao, Y. Min, A. Ray-Choudhury, J. Munasinghe, A.S. Merchant, P.C. Lin, J. Hallenbeck, M. Boehm, and L. Yang, Attenuation of Myeloid Specific TGFbeta Signaling Induces Inflammatory Cerebrovascular Disease and Stroke. Circ Res, 2017.
  14. Leyns, C.E.G. and D.M. Holtzman, Glial contributions to neurodegeneration in tauopathies. Mol Neurodegener, 2017. 12(1): p. 50.
  15. Li, B., Y. Gao, W. Zhang, and J.R. Xu, Regulation and effects of neurotrophic factors after neural stem cell transplantation in a transgenic mouse model of Alzheimer disease. J Neurosci Res, 2017.
  16. Menzel, L., L. Kleber, C. Friedrich, R. Hummel, L. Dangel, J. Winter, K. Schmitz, I. Tegeder, and M.K. Schafer, Progranulin protects against exaggerated axonal injury and astrogliosis following traumatic brain injury. Glia, 2017. 65(2): p. 278-292.
  17. Misiak, B., J.A. Beszlej, K. Kotowicz, M. Szewczuk-Boguslawska, J. Samochowiec, J. Kucharska-Mazur, and D. Frydecka, Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets. Prog Neuropsychopharmacol Biol Psychiatry, 2018. 80(Pt C): p. 177-188.
  18. Mohlenhoff, B.S., A. O’Donovan, M.W. Weiner, and T.C. Neylan, Dementia Risk in Posttraumatic Stress Disorder: the Relevance of Sleep-Related Abnormalities in Brain Structure, Amyloid, and Inflammation. Curr Psychiatry Rep, 2017. 19(11): p. 89.
  19. Paouri, E., O. Tzara, G.I. Kartalou, S. Zenelak, and S. Georgopoulos, Peripheral Tumor Necrosis Factor-Alpha (TNF-alpha) Modulates Amyloid Pathology by Regulating Blood-Derived Immune Cells and Glial Response in the Brain of AD/TNF Transgenic Mice. J Neurosci, 2017. 37(20): p. 5155-5171.
  20. Paouri, E., O. Tzara, S. Zenelak, and S. Georgopoulos, Genetic Deletion of Tumor Necrosis Factor-alpha Attenuates Amyloid-beta Production and Decreases Amyloid Plaque Formation and Glial Response in the 5XFAD Model of Alzheimer’s Disease. J Alzheimers Dis, 2017. 60(1): p. 165-181.
  21. Piirainen, S., A. Youssef, C. Song, A.V. Kalueff, G.E. Landreth, T. Malm, and L. Tian, Psychosocial stress on neuroinflammation and cognitive dysfunctions in Alzheimer’s disease: the emerging role for microglia? Neurosci Biobehav Rev, 2017. 77: p. 148-164.
  22. Rodriguez-Grande, B., A. Ichkova, S. Lemarchant, and J. Badaut, Early to Long-Term Alterations of CNS Barriers After Traumatic Brain Injury: Considerations for Drug Development. AAPS J, 2017. 19(6): p. 1615-1625.
  23. Shapira, R., B. Solomon, S. Efrati, D. Frenkel, and U. Ashery, Hyperbaric oxygen therapy ameliorates pathophysiology of 3xTg-AD mouse model by attenuating neuroinflammation. Neurobiol Aging, 2017. 62: p. 105-119.
  24. Volgyi, K., K. Haden, V. Kis, P. Gulyassy, K. Badics, B.A. Gyorffy, A. Simor, Z. Szabo, T. Janaky, L. Drahos, A. Dobolyi, B. Penke, G. Juhasz, and K.A. Kekesi, Mitochondrial Proteome Changes Correlating with beta-Amyloid Accumulation. Mol Neurobiol, 2017. 54(3): p. 2060-2078.
  25. Xu, H., Z. Wang, J. Li, H. Wu, Y. Peng, L. Fan, J. Chen, C. Gu, F. Yan, L. Wang, and G. Chen, The Polarization States of Microglia in TBI: A New Paradigm for Pharmacological Intervention. Neural Plast, 2017. 2017: p. 5405104.
  26. Yang, Y., J. Zhang, Q. Gao, J. Bo, and Z. Ma, Etanercept attenuates thermal and mechanical hyperalgesia induced by bone cancer. Experimental and Therapeutic Medicine, 2017. 13(5): p. 2565-2569.

In 2014:

*1. Bae WC, Masuda K. Chapter 25: Enhancing Disc Repair by Growth Factors and Other Modalities. In: Shapiro IM, Risbud MV, editors. The Intervertebral Disc. Wien: Springer-Verlag; 2014.

*2. Bastos LF, Coelho MM. Drug repositioning: playing dirty to kill pain. CNS Drugs. 2014;28(1):45-61.

*3. Clark IA, Vissel B. Inflammation-sleep interface in brain disease: TNF, insulin, orexin. J Neuroinflammation. 2014;11(1):51.

*4. Faingold CL. Chapter 7: Network Control Mechanisms: Cellular Inputs, Neuroactive Substances, and Synaptic Changes. In: Faingold CL, Blumenfeld H, editors. Neuronal Networks in Brain Function, CNS Disorders, and Therapeutics: Elsevier; 2014.

*5. Ferreira ST, Clarke JR, Bomfim TR, De Felice FG. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimers Dement. 2014;10(1S):S76-S83.

*6. Gisondi P, Sala F, Alessandrini F, Avesani V, Zoccatelli G, Beltramello A, et al. Mild cognitive impairment in patients with moderate to severe chronic plaque psoriasis. Dermatology. 2014;228(1):78-85.

*7. Griessenauer CJ, Raborn J, Foreman P, Shoja MM, Loukas M, Tubbs RS. Venous Drainage of the Spine and Spinal Cord: A Comprehensive Review of its History, Embryology, Anatomy, Physiology, and Pathology. Clinical Anatomy. 2014;epub.

*8. Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and Alzheimer’s disease. Rev Neurosci. 2014.

*9. Ohtori S, Inoue G, Miyagi M, Takahashi K. Pathomechanisms of discogenic low back pain in humans and animal models. Spine J. 2014.

*10. Sem DS. Repurposing – Finding New Uses for Old (and Patented) Drugs: Bridging the “Valley of Death,” to Translate Academic Research Into New Medicines. Marquette Intellectual Property Law Review. 2014;18(1):139-66.

*11. Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014.

*12. Starke RM, Raper DM, Ding D, Chalouhi N, Owens GK, Hasan DM, et al. Tumor Necrosis Factor-alpha Modulates Cerebral Aneurysm Formation and Rupture. Transl Stroke Res. 2014;5(2):269-77.

*13. Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased Plasma TACE Activity in Subjects with Mild Cognitive Impairment and Patients with Alzheimer’s Disease. Journal of Alzheimer’s disease : JAD. 2014.

*14. Trager U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFkappaB pathway dysregulation. Brain. 2014;137(Pt 3):819-33.

*15. Tronel C, Page G, Bodard S, Chalon S, Antier D. The specific PKR inhibitor C16 prevents apoptosis and IL-1beta production in an acute excitotoxic rat model with a neuroinflammatory component. Neurochem Int. 2014;64:73-83.

*16. Winkelstein BA, Allen KD, Setton LA. Chapter 19: Intervertebral Disc Herniation: Pathophysiology and Emerging Therapies. In: Shapiro IM, Risbud MV, editors. The Intervertebral Disc. Wien, Austria: Springer-Verlag; 2014.

In 2012:

1. Belarbi, K., et al., TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation, 2012. 9: p. 23.

2. Bomfim, T.R., et al., An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease- associated Abeta oligomers. J Clin Invest, 2012. 122(4): p. 1339-53.

3. Butchart, J. and C. Holmes, Systemic and central immunity in Alzheimer’s disease: therapeutic implications. CNS Neurosci Ther, 2012. 18(1): p. 64-76.

4. Cereda, C., et al., The Role of TNF-alpha in ALS: New Hypostheses for Future Therapeutic Approaches, in Amyotrophic Lateral Sclerosis, M.H. Maurer, Editor. 2012, InTech. p. 413-436.

5. Clark, I., et al., Tumor necrosis factor-induced cerebral insulin resistance in Alzheimer’s disease links numerous treatment rationales. Pharmacol Rev, 2012. 64(4): p. 1004-26.

6. Dhawan, G. and C.K. Combs, Inhibition of Src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer’s disease. J Neuroinflammation, 2012. 9: p. 117.

7. Drent, M., E.E. Lower, and J. De Vries, Sarcoidosis-associated fatigue. Eur Respir J, 2012. 40(1): p. 255-63.

8. Ferraccioli, G., et al., Rheumatoid Arthritis and Alzheimer Disease: Possible Cellular and Molecular Links. Gerontology and Geriatric, 2012. 1(1).

9. Gabbita, S.P., et al., Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J Neuroinflammation, 2012. 9: p. 99.

10. Gruber, H.E., et al., Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. Mol Pain, 2012. 8(1): p. 63.

11. Hojlund, J., et al., Effect of head rotation on cerebral blood velocity in the prone position. Anesthesiol Res Pract, 2012. 2012: p. 647258.

12. Ingles-Esteve, J., et al., Inhibition of specific NF-kappaB activity contributes to the tumor suppressor function of 14-3-3sigma in breast cancer. PLoS One, 2012. 7(5): p. e38347.

13. Jiang, T., J.T. Yu, and L. Tan, Novel disease-modifying therapies for Alzheimer’s disease. J Alzheimers Dis, 2012. 31(3): p. 475-92.

14. Krishnadas, R. and J. Cavanagh, Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry, 2012. 83(5): p. 495-502.

15. Landoni, V.I., et al., Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity. PLoS Pathog, 2012. 8(3): p. e1002632.

16. Lauterbach, E.C., Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease. Alzheimer Dis Assoc Disord, 2012. 26(1): p. 1-7.

17. Lima, A. and F. Antunes, Intervention of Physical Medicine and Rehabilitation in Failed Back Surgery Syndrome. Journal of Regional Anaesthesia and Pain Management, 2012. 68: p. 29-30.

18. Maccioni, R.B., et al., In Search of Therapeutic Solutions for Alzheimer’s Disease, in When Things Go Wrong–Diseases and Disorders of the Human Brain, T. Mantamadiotis, Editor. 2012, InTech. p. 125-.

19. Matias-Guiu, J.A. and R. Garcia-Ramos, Primary progressive aphasia: from syndrome to disease. Neurologia, 2012.

20. Montgomery, S.L. and W.J. Bowers, Tumor Necrosis Factor-alpha and the Roles it Plays in Homeostatic and Degenerative Processes Within the Central Nervous System. Journal of Neuroimmune Pharmacology, 2012. 7(1): p. 42-59.

21. Ooi, L., et al., New drugs under development for Alzheimer’s disease, in Advances in Alzheimer’s Disease Management, S. Gauthier and P. Rosa-Neto, Editors. 2012. p. 58-67.

22. Ramesh, V., et al., Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-alpha pathway. J Neuroinflammation, 2012. 9.

23. Santello, M. and A. Volterra, TNF-alpha in synaptic function: switching gears. Trends Neurosci, 2012. 35(10): p. 638-47.

24. Singh, P.L., et al., Current therapeutic strategies for inflammation following traumatic spinal cord injury. Neural Regeneration Research, 2012. 7(23): p. 1812-1821.

25. Steele, M.L. and S.R. Robinson, Reactive astrocytes give neurons less support: implications for Alzheimer’s disease. Neurobiol Aging, 2012. 33(2): p. 423 e1-13.

26. Stringer, M.D., et al., The vertebral venous plexuses: the internal veins are muscular and external veins have valves. Clin Anat, 2012. 25(5): p. 609-18.

27. Tweedie, D., et al., Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation, 2012. 9: p. 106.

28. Wilcock, D.M., Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer’s disease. Curr Gerontol Geriatr Res, 2012. 2012: p. 170276.

29. Woodward, M.C., Drug treatments in development for Alzheimer’s disease. Journal of Pharmacy Practice and Research, 2012. 42(1): p. 58-65.

30. Yoshiyama, Y., V.M. Lee, and J.Q. Trojanowski, Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry, 2012.

In 2010 and 2011:

  • Aderinwale, O.G., H.W. Ernst, and S.A. Mousa, Current therapies and new strategies for the management of Alzheimer’s disease. Am J Alzheimers Dis Other Demen, 2010. 25: (5): p. 414-24.
  • Bassi, E. and C. De Filippi, Beneficial neurological effects observed in a patient with psoriasis treated with etanercept. Am J Clin Dermatol, 2010. 11 Suppl 1: p. 44-5.
  • Boettger, M.K., et al., Spinal tumor necrosis factor alpha neutralization reduces peripheral inflammation and hyperalgesia and suppresses autonomic responses in experimental arthritis: a role for spinal tumor necrosis factor alpha during induction and maintenance of peripheral inflammation. Arthritis Rheum, 2010. 62(5): p. 1308-18.
  • Buchhave, P., et al., Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging, 2010. 31(11): p. 1877-84.
  • Candore, G., et al., Inflammation, cytokines, immune response, apolipoprotein E, cholesterol, and oxidative stress in Alzheimer disease: therapeutic implications. Rejuvenation Res, 2010. 13(2-3): p. 301-13.
  • Chavant, F., et al., Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer’s disease. J Pharmacol Exp Ther, 2010. 332(2): p. 505-14.
  • Chez, M.G. and N. Guido-Estrada, Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics, 2010. 7(3): p. 293-301.
  • Clark, I.A., L.M. Alleva, and B. Vissel, The roles of TNF in brain dysfunction and disease. Pharmacol Ther, 2010.128(3): p. 519-48.
  • Colton, C.A. and D.M. Wilcock, Assessing activation states in microglia. CNS Neurol Disord Drug Targets, 2010.9(2): p. 174-91.
  • Dumont, T.M., D.W. Stockwell, and M.A. Horgan, Venous air embolism: an unusual complication of atlantoaxial arthrodesis: case report. Spine (Phila Pa 1976), 2010. 35(22): p. E1238-40.
  • Duro, D., et al., Validation studies of the Portuguese experimental version of the Montreal Cognitive Assessment (MoCA): confirmatory factor analysis. J Neurol, 2010. 257(5): p. 728-34.
  • Elfferich, M.D., et al., Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration, 2010. 80(3): p. 212-9.
  • Esposito, E. and S. Cuzzocrea, Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci. 2011 Feb;32(2):107-15.
  • Frankola KA, Greig NH, Luo W, Tweedie D. Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases. CNS Neurol Disord Drug Targets. 2011 Feb 2. [Epub ahead of print] PMID: 21288189.
  • Furst, D.E., et al., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis, 2010. 69 Suppl 1: p. i2-29.
  • Galimberti D, Scarpini E. Alzheimer’s Disease: From Pathogenesis to Disease-Modifying Approaches. CNS & Neurological Disorders – Drug Targets March 2011. 10(2):163-174.
  • Geis, C., et al., Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain. Neuroscience, 2010. 169(1): p. 463-74.
  • Gu, X., et al., Intraperitoneal injection of thalidomide attenuates bone cancer pain and decreases spinal tumor necrosis factor-alpha expression in a mouse model. Mol Pain, 2010. 6: p. 64.
  • He, M.X., et al., Association between interleukin-6 gene promoter -572C/G polymorphism and the risk of sporadic Alzheimer’s disease. Neurol Sci, 2010. 31(2): p. 165-8.
  • Huang, H., et al., TNF{alpha} is required for late BRB breakdown in diabetic retinopathy and its inhibition prevents leukostasis and protects vessels and neurons from apoptosis. Invest Ophthalmol Vis Sci, 2011 Jan 6.
  • Landoni, V.I., et al., Shiga toxin 1-induced inflammatory response in lipopolysaccharide-sensitized astrocytes is mediated by endogenous tumor necrosis factor alpha. Infect Immun, 2010. 78(3): p. 1193-201.
  • Lanni, C., et al., The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders. Curr Pharm Des, 2010. 16(6): p. 698-717.
  • Lauterbach, E., Psychotropic Drug Effects on Gene Transcriptomics Relevant to Alzheimer Disease. Alzheimer disease and associated disorders, 2011. in press, DOI: 10.1097/WAD.0b013e318214b7d0.
  • Liu, Z.P., et al., Identifying dysfunctional crosstalk of pathways in various regions of Alzheimer’s disease brains. BMC Syst Biol, 2010. 4 Suppl 2: p. S11.
  • McIntyre, R.S., et al., Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: points of pathophysiological commonality with mood disorders? Adv Ther, 2010. 27(2): p. 63-80.
  • McNaull, B.B., et al., Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. Gerontology, 2010. 56(1): p. 3-14.
  • Menza M, Dobkin RD, Marin H, Mark MH, Gara M, Bienfait K, Dicke A, Kusnekov A. The role of inflammatory cytokines in cognition and other non-motor symptoms of Parkinson’s disease. Psychosomatics. 2010 Nov;51(6):474-9.
  • Merino, A., et al., Drug profiling: knowing where it hits. Drug Discov Today, 2010. 15(17-18): p. 749-56.
  • Money, T.T., et al., Treating schizophrenia: novel targets for the cholinergic system. CNS Neurol Disord Drug Targets, 2010. 9(2): p. 241-56.
  • Munoz, L. and A.J. Ammit, Targeting p38 MAPK pathway for the treatment of Alzheimer’s disease. Neuropharmacology, 2010. 58(3): p. 561-8.
  • Nicolae, C. and B.R. Olsen, Unexpected matrix diseases and novel therapeutic strategies. Cell Tissue Res, 2010.339(1): p. 155-65.
  • Oldreive, C.E. and G.H. Doherty, Effects of tumour necrosis factor-alpha on developing cerebellar granule and Purkinje neurons in vitro. J Mol Neurosci, 2010. 42(1): p. 44-52.
  • Pan, S.Y., et al., New perspectives on innovative drug discovery: an overview. J Pharm Pharm Sci, 2010. 13(3): p. 450-71.
  • Potter, P.E., Investigational medications for treatment of patients with Alzheimer disease. J Am Osteopath Assoc, 2010.110(9 Suppl 8): p. S27-36.
  • Ramanan, S., et al., Role of PPARs in Radiation-Induced Brain Injury. PPAR Res, 2010. 2010: p. 234975.
  • Seigers, R. and J.E. Fardell, Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev, 2011. 35(3): p. 729-41.
  • Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J. Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res. 2011 Jan 12;1368:239-47.
  • Simen AA, Bordner KA, Martin MP, et. al., Cognitive dysfunction with aging and the role of inflammation. Therapeutic Advances in Chronic Disease, 2011. Published online before print February 15, 2011, doi:10.1177/2040622311399145.
  • Sinclair, S.M., et al., Attenuation of Inflammatory Events in Human Intervertebral Disc Cells with a Tumor Necrosis Factor Antagonist. Spine (Phila Pa 1976), 2011 Jan 6.
  • Tamayo AC, Guajardo-Rosas J. Cervical epidural injections for radicular pain. Techniques in Regional Anesthesia and Pain Management. Volume 14, Issue 3, July 2010, Pages 106-112.
  • Vinukonda, G., et al., Neuroprotection in a rabbit model of intraventricular haemorrhage by cyclooxygenase-2, prostanoid receptor-1 or tumour necrosis factor-alpha inhibition. Brain, 2010. 133(Pt 8): p. 2264-80.
  • Wang, M.J., et al., Glycogen synthase kinase-3beta inactivation inhibits tumor necrosis factor-alpha production in microglia by modulating nuclear factor kappaB and MLK3/JNK signaling cascades. J Neuroinflammation, 2010. 7: p. 99.
Please see the following publications by scientists independent of the INR for additional scientific background:
 

 Relevant Scientific Publications

Relevant Scientific References: 2012-2013[1-41] 2003-2011[42-118]

*Asterisk indicates that the designated Scientific Reference has cited one of more of the scientific publications of Edward Tobinick

*1.            Acton QA: Chapter 15: Neurotherapeutics. In Issues in Neurological Surgery and Specialties: 2011 Edition. Edited by Acton QA. Atlanta, Georgia: ScholarlyEditions; 2012: 1601-1631

*2.            Belarbi K, Jopson T, Tweedie D, Arellano C, Luo W, Greig NH, Rosi S: TNF-alpha protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J Neuroinflammation 2012, 9:23.

3.            Chou SH, Feske SK, Atherton J, Konigsberg RG, De Jager PL, Du R, Ogilvy CS, Lo EH, Ning M: Early Elevation of Serum Tumor Necrosis Factor-alpha Is Associated With Poor Outcome in Subarachnoid Hemorrhage. J Investig Med 2012.

*4.            Clark I: New hope for survivors of stroke and traumatic brain injury. CNS Drugs 2012, 26:1071-1072.

*5.            Clark I, Atwood C, Bowen R, Paz-Filho G, Vissel B: Tumor Necrosis Factor-Induced Cerebral Insulin Resistance in Alzheimer’s Disease Links Numerous Treatment Rationales. Pharmacological Reviews 2012, 64:1004-1026.

*6.            Delrieu J, Piau A, Vellas B: Chapter 78: Drug Development and Alzheimer’s Disease. In Pathy’s Principles and Practice of Geriatric Medicine, Fifth Edition. Edited by Sinclair AJ, Morley JE, Vellas B. West Sussex, UK: Wiley-Blackwell; 2012

*7.            Elcioglu H, Kabasakal L, Alan S, Salva E, Tufan F, Karan M: Thalidomide attenuates learning and memory deficits induced by intracerebroventricular administration of streptozotocin in rats. Biotech Histochem 2012.

*8.            Ferraccioli G, Gremese E, Carbonella A, Alivernini S: Rheumatoid Arthritis and Alzheimer Disease: Possible Cellular and Molecular Links. J Gerontol Geriatric Res 2012, 1:e104.

*9.            Gabbita SP, Srivastava MK, Eslami P, Johnson MF, Kobritz NK, Tweedie D, Greig NH, Zemlan FP, Sharma SP, Harris-White ME: Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer’s disease. J Neuroinflammation 2012, 9:99.

*10.            Gruber HE, Hoelscher GL, Ingram JA, Hanley EN, Jr.: Genome-wide analysis of pain-, nerve- and neurotrophin -related gene expression in the degenerating human annulus. Mol Pain 2012, 8:63.

*11.            Jiang T, Yu JT, Tan L: Novel disease-modifying therapies for Alzheimer’s disease. J Alzheimers Dis 2012, 31:475-492.

*12.            Lauterbach EC: Psychotropic drug effects on gene transcriptomics relevant to Alzheimer disease. Alzheimer Dis Assoc Disord 2012, 26:1-7.

*13.            Maccioni RB, Farias G, Rojo LE, Jimenez JM: In Search of Therapeutic Solutions for Alzheimer’s Disease. In When Things Go Wrong – Diseases and Disorders of the Human Brain. Edited by Mantamadiotis T. Rijeka, Croatia: InTech; 2012: 125-150

*14.            Matias-Guiu JA, Garcia-Ramos R: Primary progressive aphasia: from syndrome to disease. Neurologia 2012.

*15.            Maudsley S, Chadwick W: Progressive and unconventional pharmacotherapeutic approaches to Alzheimer’s disease therapy. Curr Alzheimer Res 2012, 9:1-4.

16.            Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, Kishida S, Kuniyoshi K, Nakamura J, Aoki Y, et al: Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine (Phila Pa 1976) 2012, 37:439-444.

*17.            Ooi L, al. e: New Drugs Under Development for Alzheimer’s Disease. In Advances in Alzheimer’s Disease Management. Edited by Gauthier S, Rosa-Neto P; 2012: 58-67

*18.            Raffaghello L, Bianchi G, Pistoia V: Immunosuppressive treatments in acute myocardial infarction and stroke. Curr Pharm Biotechnol 2012, 13:59-67.

*19.            Ramesh V, Nair D, Zhang SX, Hakim F, Kaushal N, Kayali F, Wang Y, Li RC, Carreras A, Gozal D: Disrupted sleep without sleep curtailment induces sleepiness and cognitive dysfunction via the tumor necrosis factor-alpha pathway. J Neuroinflammation 2012, 9:91.

20.            Roh M, Zhang Y, Murakami Y, Thanos A, Lee SC, Vavvas DG, Benowitz LI, Miller JW: Etanercept, a widely used inhibitor of tumor necrosis factor-alpha (TNF-alpha), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One 2012, 7:e40065.

*21.            Santello M, Volterra A: TNFalpha in synaptic function: switching gears. Trends Neurosci 2012, 35:638-647.

22.            Smith C, Gentleman SM, Leclercq PD, Murray LS, Griffin WS, Graham DI, Nicoll JA: The neuroinflammatory response in humans after traumatic brain injury. Neuropathol Appl Neurobiol 2012.

*23.            Smith JA, Das A, Ray SK, Banik NL: Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012, 87:10-20.

*24.            Steele ML, Robinson SR: Reactive astrocytes give neurons less support: implications for Alzheimer’s disease. Neurobiol Aging 2012, 33:423 e421-413.

*25.            Tobinick E: Deciphering the physiology underlying the rapid clinical effects of perispinal etanercept in Alzheimer’s disease. Curr Alzheimer Res 2012, 9:99-109.

*26.            Tobinick E, Kim NM, Reyzin G, Rodriguez-Romanacce H, Depuy V: Selective TNF Inhibition for Chronic Stroke and Traumatic Brain Injury : An Observational Study Involving 629 Consecutive Patients Treated with Perispinal Etanercept. CNS Drugs 2012, 26:1051-1070.

*27.            Tweedie D, Ferguson RA, Fishman K, Frankola KA, Van Praag H, Holloway HW, Luo W, Li Y, Caracciolo L, Russo I, et al: Tumor necrosis factor-alpha synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer’s disease. J Neuroinflammation 2012, 9:106.

*28.            Wilcock DM: Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer’s disease. Curr Gerontol Geriatr Res 2012, 2012:170276.

*29.            Williams M, Coyle JT: Chapter 7: Historical perspectives on the discovery and development of drugs to treat neurological disorders. In Translational Neuroscience: Applications in Psychiatry, Neurology, and Neurodevelopmental Disorders. Edited by Barrett JE, Coyle JT, Williams M. Cambridge, England: Cambridge University Press; 2012: 129-148

*30.            Yoshiyama Y, Lee VM, Trojanowski JQ: Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry 2012.

*31.            Bai L, Song N, Yu J, Tan L, Shen Y, Xie J, Jiang H: Elevated Plasma Levels of Soluble TNFRs and TACE Activity in Alzheimer’s Disease Patients of Northern Han Chinese Descent. Curr Alzheimer Res 2013, 10:57-62.

*32.            Brambilla L, Martorana F, Rossi D: Astrocyte signaling and neurodegeneration: New insights into CNS disorders. Prion 2013, 7:28-36.

33.            Chio CC, Chang CH, Wang CC, Cheong CU, Chao CM, Cheng BC, Yang CZ, Chang CP: Etanercept attenuates traumatic brain injury in rats by reducing early microglial expression of tumor necrosis factor-alpha. BMC Neurosci 2013, 14:33.

34.            Griffin WS: Neuroinflammatory cytokine signaling and Alzheimer’s disease. N Engl J Med 2013, 368:770-771.

35.            Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W: Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain 2013, 136:28-42.

36.            King MD, Alleyne CH, Jr., Dhandapani KM: TNF-alpha receptor antagonist, R-7050, improves neurological outcomes following intracerebral hemorrhage in mice. Neurosci Lett 2013.

37.            Kumar A, Stoica BA, Sabirzhanov B, Burns MP, Faden AI, Loane DJ: Traumatic brain injury in aged animals increases lesion size and chronically alters microglial/macrophage classical and alternative activation states. Neurobiol Aging 2013, 34:1397-1411.

*38.            Liu Q, Jin L, Mahon BH, Chordia MD, Shen FH, Li X: A Novel Treatment of Neuroinflammation Against Low Back Pain by Soluble Fullerol Nanoparticles. Spine (Phila Pa 1976) 2013.

39.            Niranjan R: Molecular Basis of Etiological Implications in Alzheimer’s Disease: Focus on Neuroinflammation. Mol Neurobiol 2013.

40.            O’Connor JJ: Targeting tumour necrosis factor-alpha in hypoxia and synaptic signalling. Ir J Med Sci 2013, 182:157-162.

*41.            Swardfager W, Winer DA, Herrmann N, Winer S, Lanctot KL: Interleukin-17 in post-stroke neurodegeneration. Neurosci Biobehav Rev 2013, 37:436-447.

42.            Tarkowski E, Andreasen N, Tarkowski A, Blennow K: Intrathecal inflammation precedes development of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2003, 74:1200-1205.

*43.            Tobinick EL, Britschgi-Davoodifar S: Perispinal TNF-alpha inhibition for discogenic pain. Swiss Med Wkly 2003, 133:170-177.

44.            Gentleman SM, Leclercq PD, Moyes L, Graham DI, Smith C, Griffin WS, Nicoll JA: Long-term intracerebral inflammatory response after traumatic brain injury. Forensic Sci Int 2004, 146:97-104.

45.            Sjogren M, Folkesson S, Blennow K, Tarkowski E: Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry 2004, 75:1107-1111.

*46.            Tobinick E, Davoodifar S: Efficacy of etanercept delivered by perispinal administration for chronic back and/or neck disc-related pain: a study of clinical observations in 143 patients. Curr Med Res Opin 2004, 20:1075-1085.

*47.            Inglis JJ, Hunt SP, Kidd BL: Mechanisms of Inflammatory Hyperalgesia. In From Basic Pain Mechanisms to Headache. Edited by Olesen J, Jensen T. Oxford, England: Oxford University Press; 2006

*48.            Myers RR, Campana WM, Shubayev VI: The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov Today 2006, 11:8-20.

*49.            Tobinick E, Gross H, Weinberger A, Cohen H: TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. MedGenMed 2006, 8:25.

50.            Tobinick E, Vega CP: The cerebrospinal venous system: anatomy, physiology, and clinical implications. MedGenMed 2006, 8:53.

*51.            DanaAlliance: The 2007 Progress Report on Brain Research. New York: Dana Press; 2007.

*52.            DeWitte M, Shealy DJ, Nakada MT, Anderson GM: Chapter 4: Tumor Necrosis Factor and Cancer. In Cytokines in the Genesis and Treament of Cancer. Edited by Caligiuri MA, Lotze MT. Totowa, N.J.: Humana Press; 2007: 71-90

*53.            do Couto FS, de Mendonca A: Chapter 11: Aging and Cognitive Decline: Neuroprotective Strategies. In Interaction Between Neurons and Glia in Aging and Disease. Edited by Malva JO. New York, N.Y.: Springer; 2007: 245-268

*54.            Tobinick E: Perispinal etanercept for treatment of Alzheimer’s disease. Curr Alzheimer Res 2007, 4:550-552.

*55.            Tweedie D, Sambamurti K, Greig NH: TNF-alpha Inhibition as a Treatment Strategy for Neurodegenerative Disorders: New Drug Candidates and Targets. Curr Alzheimer Res 2007, 4:375-378.

*56.            Van Eldik LJ, Thompson WL, Ranaivo HR, Behanna HA, Watterson DM: Glia Proinflammatory Cytokine Upgregulation as a Therapeutic Target for Neurodegenerative Disease: Function-Based and Target-Based Discovery Approaches. In Neuroinflammation in Neuronal Death and Repair. Edited by Bagetta G: Elsevier; 2007: 278-297

*57.            Auffray C: Evaluations for Tobinick, EL and Gross H J of Neuroinflammation. Faculty of 1000 Biology 2008, 5:2.

*58.            Griffin WS: Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflammation 2008, 5:3.

*59.            Ignatowski TA, Spengler RN: II. Cytokines in the Brain, B. Cytokines in Brain Physiology: Cytokines in Synaptic Function. In NeuroImmune Biology, Vol 6: Cytokines and the Brain. Edited by Phelps C, Korneva E. Amsterdam, The Netherlands: Elsevier; 2008: 111-144

60.            Kaushal V, Schlichter LC: Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28:2221-2230.

*61.            Tansey MG, Wyss-Coray T: Cytokines in CNS Inflammation and Disease. In Central Nervous System Diseases and Inflammation. Edited by Lane TE, Carson M, Bergmann C, Wyss-Coray T. New York, N.Y.: Springer; 2008: 59-106

*62.            Tobinick E: Perispinal etanercept produces rapid improvement in primary progressive aphasia: identification of a novel, rapidly reversible TNF-mediated pathophysiologic mechanism. Medscape J Med 2008, 10:135.

*63.            Tobinick EL, Gross H: Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflammation 2008, 5:2.

*64.            Tobinick EL, Gross H: Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 2008, 8:27.

65.            Youn DH, Wang H, Jeong SJ: Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res 2008, 86:2867-2875.

*66.            Zanella JM, Burright EN, Hildebrand K, Hobot C, Cox M, Christoferson L, McKay WF: Effect of etanercept, a tumor necrosis factor-alpha inhibitor, on neuropathic pain in the rat chronic constriction injury model. Spine (Phila Pa 1976) 2008, 33:227-234.

*67.            Bruni JE, Montemurro DG: Chapter 4: Blood Supply of the Nervous System. In Human Neuroanatomy: A Text, Brain Atlas, and Laboratory Dissection Guide. Edited by Bruni JE, Montemurro DG. New York, N.Y.: Oxford University Press, Inc.; 2009: 51-64

68.            Esposito E, Cuzzocrea S: TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009, 16:3152-3167.

*69.            Furrer E, Hulmann V, Urech DM: Intranasal delivery of ESBA105, a TNF-alpha-inhibitory scFv antibody fragment to the brain. J Neuroimmunol 2009, 215:65-72.

*70.            Giuliani F, Vernay A, Leuba G, Schenk F: Decreased behavioral impairments in an Alzheimer mice model by interfering with TNF-alpha metabolism. Brain Res Bull 2009, 80:302-308.

*71.            Kato K, Kikuchi S, Shubayev VI, Myers RR: Distribution and tumor necrosis factor-alpha isoform binding specificity of locally administered etanercept into injured and uninjured rat sciatic nerve. Neuroscience 2009, 160:492-500.

72.            Marchand F, Tsantoulas C, Singh D, Grist J, Clark AK, Bradbury EJ, McMahon SB: Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain 2009, 13:673-681.

*73.            McAfoose J, Baune BT: Evidence for a cytokine model of cognitive function. Neurosci Biobehav Rev 2009, 33:355-366.

*74.            Tarditi A, Caricasole A, Terstappen G: Therapeutic targets for Alzheimer’s disease. Expert Opin Ther Targets 2009, 13:551-567.

*75.            Tobinick E: Perispinal etanercept for neuroinflammatory disorders. Drug Discov Today 2009, 14:168-177.

*76.            Tobinick E: Tumour necrosis factor modulation for treatment of Alzheimer’s disease: rationale and current evidence. CNS Drugs 2009, 23:713-725.

*77.            Tobinick EL, Chen K, Chen X: Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging. BMC Res Notes 2009, 2:28.

*78.            Yiannopoulou K: Therapeutic targets in Alzheimer’s disease. Primary Psychiatry 2009, 16:29-36.

*79.            Alamin TF, Agarwal V: Chapter 5: The Mechanisms of Pain from Intervertebral Discs. In The Lumbar Intervertebral Disc. Edited by Phillips FM, Lauryssen C: Thieme Medical Publishers, Inc.; 2010

*80.            Beattie MS, Ferguson AR, Bresnahan JC: AMPA-receptor trafficking and injury-induced cell death. Eur J Neurosci 2010.

*81.            Buchhave P, Zetterberg H, Blennow K, Minthon L, Janciauskiene S, Hansson O: Soluble TNF receptors are associated with Abeta metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiol Aging 2010, 31:1877-1884.

*82.            Chakrabarty P: Current and future therapies for Alzheimer’s disease. In Protein misfolding diseases: Current and emerging principles and therapies. 2010: 711-774

*83.            Chen YM, Chen HH, Lan JL, Chen DY: Improvement of cognition, a potential benefit of anti-TNF therapy in elderly patients with rheumatoid arthritis. Joint Bone Spine 2010, 77:366-367.

*84.            Chio CC, Lin JW, Chang MW, Wang CC, Yang CZ, Chang CP: Therapeutic evaluation of etanercept in a model of traumatic brain injury. J Neurochem 2010, 115:921-929.

*85.            Clark IA, Alleva LM, Vissel B: The roles of TNF in brain dysfunction and disease. Pharmacol Ther 2010, 128:519-548.

*86.            Colton C, Wilcock DM: Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174-191.

*87.            Elfferich MD, Nelemans PJ, Ponds RW, De Vries J, Wijnen PA, Drent M: Everyday cognitive failure in sarcoidosis: the prevalence and the effect of anti-TNF-alpha treatment. Respiration 2010, 80:212-219.

88.            Hachinski V, Donnan GA, Gorelick PB, Hacke W, Cramer SC, Kaste M, Fisher M, Brainin M, Buchan AM, Lo EH, et al: Stroke: working toward a prioritized world agenda. Stroke 2010, 41:1084-1099.

89.            Hughes JL, Beech JS, Jones PS, Wang D, Menon DK, Baron JC: Mapping selective neuronal loss and microglial activation in the salvaged neocortical penumbra in the rat. Neuroimage 2010, 49:19-31.

*90.            Kato K, Liu H, Kikuchi S, Myers RR, Shubayev VI: Immediate anti-tumor necrosis factor-alpha (etanercept) therapy enhances axonal regeneration after sciatic nerve crush. J Neurosci Res 2010, 88:360-368.

*91.            Labbate LA: Drugs for the Treatment of Dementia. In Handbook of Psychiatric Drug Therapy, 6th Edition. 6th edition. Edited by Labbate LA. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2010: 254-264

*92.            McNaull BB, Todd S, McGuinness B, Passmore AP: Inflammation and anti-inflammatory strategies for Alzheimer’s disease–a mini-review. Gerontology 2010, 56:3-14.

*93.            Park KM, Bowers WJ: Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal 2010, 22:977-983.

*94.            Tobinick E: Perispinal etanercept: a new therapeutic paradigm in neurology. Expert Rev Neurother 2010, 10:985-1002.

*95.            Baratz R, Tweedie D, Rubovitch V, Luo W, Yoon JS, Hoffer BJ, Greig NH, Pick CG: Tumor necrosis factor-alpha synthesis inhibitor, 3, 6‚-thiothalidomide, reverses behavioral impairments induced by minimal traumatic brain injury in mice. Journal of neurochemistry 2011.

*96.            Budson AE, Kowall NW: Chapter 10: Towards an Effective Therapy for AD. In The Handbook of Alzheimer’s Disease and Other Dementias. Edited by Budson AE, Kowall NW. Malden, Massachussetts: Wiley-Blackwell; 2011: 301-311

*97.            Cavanagh C, Colby-Milley J, Farso M, Krantic S, Quirion R: Early molecular and synaptic dysfunctions in the prodromal stages of Alzheimer’s disease; focus on TNF-alpha and IL-1beta. Future Neurology 2011, 6:757-769.

*98.            Esposito E, Cuzzocrea S: Anti-TNF therapy in the injured spinal cord. Trends Pharmacol Sci 2011, 32:107-115.

99.            Folkersma H, Boellaard R, Yaqub M, Kloet RW, Windhorst AD, Lammertsma AA, Vandertop WP, van Berckel BN: Widespread and prolonged increase in (R)-(11)C-PK11195 binding after traumatic brain injury. J Nucl Med 2011, 52:1235-1239.

*100.            Frankola KA, Greig NH, Luo W, Tweedie D: Targeting TNF-alpha to elucidate and ameliorate neuroinflammation in neurodegenerative diseases. CNS Neurol Disord Drug Targets 2011, 10:391-403.

*101.            Hakim AM: Depression, Strokes and Dementia: New Biological Insights into an Unfortunate Pathway. Cardiovascular Psychiatry and Neurology 2011, 2011.

*102.            Jain KK: Chapter 8: Neuroprotection in Alzheimer’s Disease. In The Handbook of Neuroprotection. Edited by Jain KK. Basel, Switzerland: Humana Press; 2011: 337-368

*103.            Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y: Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer’s disease. Mol Neurodegener 2011, 6:69.

*104.            Jicha GA, Nelson PT: Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Management 2011, 1:141-156.

*105.            Li M, Soczynska JK, Kennedy SH: Inflammatory biomarkers in depression: An opportunity for novel therapeutic interventions. Current psychiatry reports 2011:1-5.

*106.            Li X, Cudaback E, Keene CD, Breyer RM, Montine TJ: Suppressed microglial E prostanoid receptor 1 signaling selectively reduces tumor necrosis factor alpha and interleukin 6 secretion from toll‚Äêlike receptor 3 activation. Glia 2011, 59:569-576.

*107.            Nathoo N, Caris EC, Wiener JA, Mendel E: History of the vertebral venous plexus and the significant contributions of Breschet and Batson. Neurosurgery 2011, 69:1007-1014; discussion 1014.

*108.            Olgiati P, Politis AM, Papadimitriou GN, De Ronchi D, Serretti A: Genetics of Late-Onset Alzheimer’s Disease: Update from the Alzgene Database and Analysis of Shared Pathways. International Journal of Alzheimer’s Disease 2011, 2011.

*109.            Piau A, Nourhashmi F, Hein C, Caillaud C, Vellas B: Progress in the development of new drugs in Alzheimer’s disease. The journal of nutrition, health & aging 2011, 15:45-57.

110.            Ramlackhansingh AF, Brooks DJ, Greenwood RJ, Bose SK, Turkheimer FE, Kinnunen KM, Gentleman S, Heckemann RA, Gunanayagam K, Gelosa G, Sharp DJ: Inflammation after trauma: microglial activation and traumatic brain injury. Ann Neurol 2011, 70:374-383.

*111.            Rossi D, Martorana F, Brambilla L: Implications of gliotransmission for the pharmacotherapy of CNS disorders. CNS Drugs 2011, 25:641-658.

*112.            Roth JL, Ott BR, Gaitanis JN, Blum AS: Chapter 15: The Neuroimmunology of Cortical Disease. In Clinical Neuroimmunology: Multiple Sclerosis and Related Disorders. Edited by Rizvi SA, Coyle PK. New York: Humana Press; 2011: 275-290

*113.            Seigers R, Fardell JE: Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neuroscience & Biobehavioral Reviews 2011, 35:729-741.

*114.            Shen CH, Tsai RY, Shih MS, Lin SL, Tai YH, Chien CC, Wong CS: Etanercept restores the antinociceptive effect of morphine and suppresses spinal neuroinflammation in morphine-tolerant rats. Anesth Analg 2011, 112:454-459.

*115.            Shi JQ, Shen W, Chen J, Wang BR, Zhong LL, Zhu YW, Zhu HQ, Zhang QQ, Zhang YD, Xu J: Anti-TNF-alpha reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains. Brain Res 2011, 1368:239-247.

*116.            Simen AA, Bordner KA, Martin MP, Moy LA, Barry LC: Cognitive dysfunction with aging and the role of inflammation. Therapeutic Advances in Chronic Disease 2011, 2:175-195.

*117.            Tobinick E: Rapid improvement of chronic stroke deficits after perispinal etanercept: three consecutive cases. CNS Drugs 2011, 25:145-155.

*118.            Townsend M: When Will Alzheimer’s Disease be Cured? A Pharmaceutical Perspective. Journal of Alzheimer’s Disease 2011, 24:43-52.

*Indicates that the Scientific Reference listed has cited one of more of the scientific publications of Edward Tobinick